Bar graphs show the relative level of expression of 15 of the differentially expressed genes in paired myometrium (M) and leiomyomas (L) from Caucasians (C) and African Americans (AA) determined by realtime PCR low density array

<p><b>Copyright information:</b></p><p>Taken from "Genomic and proteomic profiling I: Leiomyomas in African Americans and Caucasians"</p><p>http://www.rbej.com/content/5/1/34</p><p>Reproductive biology and endocrinology : RB&E 2007;5():34-34.</p><p>Published online 23 Aug 2007</p><p>PMCID:PMC2063502.</p><p></p> Values on the y-axis represent an arbitrary unit derived from the mean expression of each gene independently with the mean value of myometrium from Caucasian set at 1 for each gene. The asterisks * are statistically different from ** comparing paired myometrium and leiomyomas from African Americans and Caucasians with arrows pointing out the difference between the expression of these genes in leiomyoma and myometrium in each group. A probability level of P < 0.05 was considered significant

Cluster analysis of 206 differentially expressed genes in leiomyomas from Caucasians (CL1, CL2, and CL3) and peritoneal adhesions (A1, A2, A3) using Affymetrix U95 array

<p><b>Copyright information:</b></p><p>Taken from "Genomic and proteomic profiling II: Comparative assessment of gene expression profiles in leiomyomas, keloids, and surgically-induced scars"</p><p>http://www.rbej.com/content/5/1/35</p><p>Reproductive biology and endocrinology : RB&E 2007;5():35-35.</p><p>Published online 24 Aug 2007</p><p>PMCID:PMC2039739.</p><p></p> The genes were selected based on supervised and unsupervised assessment and p ranking at P < 0.01 followed by 2-fold cutoff change selection. The genes represented by rows were clustered according to their similarities in expression patterns for each tissue and identified as A and B

The bar graphs show the relative mean expression levels of 12 genes (E2F1, RUNX3, EGR3, TBPIP, ECM-2 ESM1, THBS1, GAS1, ADAM17, CST6, FBLN5, and COL18A1) in leiomyomas (LYM), keloids/incisional scars (Scar) and peritoneal adhesions (P

<p><b>Copyright information:</b></p><p>Taken from "Genomic and proteomic profiling II: Comparative assessment of gene expression profiles in leiomyomas, keloids, and surgically-induced scars"</p><p>http://www.rbej.com/content/5/1/35</p><p>Reproductive biology and endocrinology : RB&E 2007;5():35-35.</p><p>Published online 24 Aug 2007</p><p>PMCID:PMC2039739.</p><p></p> Adhesion) using realtime PCR and LDA as described in materials and methods section. Values on the y-axis represent an arbitrary unit derived from the mean expression level of these genes in each tissue with their mean expression values in leiomyomas set at 1 independently for each gene prior to normalization against their expression levels in myometrium form a Caucasian serving as control. The asterisks * indicate statistical difference between the expression of these genes with arrows pointing the difference between each group. A probability level of P < 0.05 was considered significant

<i>CXCL5</i> expression is modulated by atorvastatin and IL-1β.

<p>(A) Gel electrophoresis of <i>CXCL5</i> and <i>GAPDH</i> PCR products; (B) Log₁₀ relative quantification of <i>CXCL5</i> modulated by atorvastatin, IL-1β, and their combination normalized to <i>GAPDH</i> (N = 2 experiments). *P<0.005, †P<0.0001. AT, atorvastatin.</p

Atorvastatin effects on ENA-78 are reversed by mevalonate and its downstream metabolites.

<p>Data are presented as mean±SEM of 10 experiments. *p<0.001 and †p = 0.05 compared to IL-1β stimulation alone. AT, atorvastatin; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate; MEV, mevalonate.</p

Kaplan Meier estimates for all-cause mortality by <i>CXCL5</i> −156 G>C genotype.

<p>Panel A represents the overall population; panel B represents the Caucasians only.</p

Adjusted hazard ratio and 95% confidence intervals for all-cause mortality by genotype.

<p>Top panel is overall population (p = 0.017) and bottom panel is Caucasians only (p = 0.043). Models adjusted for age, race, sex, ACS type, revascularization strategy, history of diabetes, and history of heart failure.</p

Baseline Characteristics.

<p>*n = 603; ^†n = 594; ^‡n = 565; ^§n = 593; ACS = Acute coronary syndrome; MI = Myocardial infarction; LBB = Left bundle block; HTN = Hypertension; BMI = Body mass index; EF = Ejection fraction; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; HDL = High density lipoprotein; LDL = Low density lipoprotein; PCI = Percutaneous coronary intervention; CABG = Coronary artery bypass graft.</p

Atorvastatin attenuates ENA-78 production over time.

<p>Levels are relative to baseline (0 hour) for each condition. Data are presented as mean±SEM of 4 experiments. *p≤0.01. —○—, IL-1β stimulation+atorvastatin 10 µM; —•—, IL-1β stimulation alone; AT, atorvastatin.</p

Atorvastatin attenuates IL-1β-induced ENA-78 production in a dose-dependent fashion.

<p>Data are presented as mean±SEM of 4 experiments. * p<0.0001 vs. IL-1β, †p = NS vs. control. AT, atorvastatin.</p